In this PACUPod overview, hosts Britany and Seth examine Wake et al.'s study on anti-angiogenic therapy for advanced hepatocellular carcinoma (HCC). They discuss how treatments like atezolizumab-bevacizumab and lenvatinib can cause non-tumoral liver volume loss, sometimes independent of tumor shrinkage, and the clinical implications for liver function monitoring, dosing decisions, and patient selection. The episode highlights practical takeaways for clinicians and pharmacists, the study's limitations, and future research directions, including potential integration of liver volumetry into routine management and the need to balance efficacy with preservation of liver reserve.